Company Profile
aTyr Pharma Stock Price, News & Analysis
- Ticker:
- ATYR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.50 USD (-5.10%)
Close
Last updated: August 6, 2026
51M USD
Market cap
Why the stock is moving
The latest monitored company update is “aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD.” The corresponding closing-price reaction is not yet available.
Company overview
tRNA Synthetase Biology
aTyr Pharma is a clinical-stage biotechnology company translating extracellular signaling functions of tRNA synthetases into therapies for fibrosis and inflammation. Its discovery platform searches domains derived from the 20 human tRNA synthetases for new therapeutic intervention points.
Efzofitimod
Efzofitimod is a tRNA synthetase-derived biologic immunomodulator designed to act through neuropilin-2 on activated myeloid cells. The candidate is intended to resolve inflammation and potentially limit fibrosis without broad immune suppression.
Interstitial Lung Disease Focus
Development is concentrated on interstitial lung diseases. aTyr is preparing a Phase 3 program in pulmonary sarcoidosis and has completed enrollment in the Phase 2 EFZO-CONNECT study in systemic sclerosis-associated interstitial lung disease.
Future catalysts
FDA feedback on the submitted pulmonary-sarcoidosis Phase 3 protocol by the end of August 2026.
Topline results from the Phase 2 EFZO-CONNECT study of efzofitimod in systemic sclerosis-associated interstitial lung disease in the first quarter of 2027.
Recent news
- 01
- 02
- 03
- 04
aTyr Pharma to Participate in Upcoming Investor Conferences
Source: aTyr Pharma
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of aTyr Pharma (ATYR)?
aTyr Pharma (ATYR) most recently closed at 0.50 USD, a -5.10% move versus the previous session.
What is the market cap of aTyr Pharma (ATYR)?
aTyr Pharma currently has a market capitalization of 51M USD on BioPharmSignal.
What does aTyr Pharma do?
tRNA Synthetase Biology aTyr Pharma is a clinical-stage biotechnology company translating extracellular signaling functions of tRNA synthetases into therapies for fibrosis and inflammation. Its discovery platform searches domains derived from the 20 human tRNA synthetases for new therapeutic intervention points. Efzofitimod Efzofitimod is a tRNA...
On which exchange is ATYR stock listed?
aTyr Pharma (ATYR) is associated with NASDAQ, United States, Biopharma.
What is EFZO-CONNECT?
Topline results from the Phase 2 EFZO-CONNECT study of efzofitimod in systemic sclerosis-associated interstitial lung disease in the first quarter of 2027.
Which conditions is aTyr Pharma targeting with EFZO-CONNECT?
aTyr Pharma is associated with inflammatory disease based on its company overview and current catalyst commentary.
How does aTyr Pharma describe recent progress with EFZO-CONNECT?
Topline results from the Phase 2 EFZO-CONNECT study of efzofitimod in systemic sclerosis-associated interstitial lung disease in the first quarter of 2027.
What is Synthetase?
tRNA Synthetase Biology aTyr Pharma is a clinical-stage biotechnology company translating extracellular signaling functions of tRNA synthetases into therapies for fibrosis and inflammation.